Its about risk to reward, at $25m m/c the up side is a lot greater than the down side. Rhinomed is in a unique situation where they have a revolutionary product at the right time and they are going to launch it in a matter of weeks if not days.
CGP shares a few similarities with the ISN story. For many years ISN were just doing nothing, until two and a half years ago Michael Thomas became the CEO of Isonea, there were a few changes in management out with the old management in with new management, and they have done a remarkable job in marketing their product. There sp has risen amazingly also.
What Im trying to say is it takes great management to get a product of the ground. Rhinomed have the right people in place, Michael Johnson the CEO of Rhinomed has a marketing back ground, he is a director of Melbourne based cogentum, a marketing strategy firm that has successfully assisted many of the sectors tops companies in the commercialisation of their assets. Including advising the team at Acrux (ACR) with successful licensing of Axiron with Eli Lilly.
Martin Rogers the chairman, was the former CEO of Prima Biomed has experience in all aspects of financial, strategic and operational management and has helped raise over $100m in cash equity along the way.
Chief marketing officer Jane Ballantyne was the former Nike brand marketing manager and AFL marketing manager. Just think about all her contacts in the industry.
Im sure management will do what ever it takes to get brand awareness out there to the public, as I have said over and over again they have the right team in place to make things happen.
dyor
CGP Price at posting:
7.7¢ Sentiment: LT Buy Disclosure: Held
